Back to Infectious Disease
Infectious Diseasev2023 FDAEvidence-Based

Indications for Paxlovid

Aids in determining if Paxlovid (nirmatrelvir boosted with ritonavir) is appropriate therapy in an adult COVID-19 positive patient. Paxlovid is an oral antiviral treatment authorized for mild-to-moderate COVID-19 in patients at high risk for progression to severe COVID-19, including hospitalization or death. The tool evaluates eligibility based on FDA guidelines including age, weight, symptom duration, disease severity, kidney function, high-risk conditions, and potential contraindications. Proper patient selection is crucial as the medication must be started within 5 days of symptom onset and has significant drug interactions requiring careful evaluation. The assessment helps clinicians systematically determine appropriate candidates for this time-sensitive antiviral therapy.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
recommendation
—recommendation
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Indications for Paxlovid is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within infectious disease.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Eligibility = All basic criteria met (age >12, weight >40kg, mild-moderate disease, ≤5 days symptoms, eGFR >30, no severe hepatic impairment) AND at least one high-risk factor AND no significant contraindications

Clinical Pearls & Practice Notes

  • Must be started within 5 days of COVID-19 symptom onset for efficacy
  • Check for drug interactions with ritonavir (strong CYP3A4 inhibitor)
  • Standard dose: nirmatrelvir 300mg + ritonavir 100mg twice daily for 5 days
  • Reduced dose for moderate renal impairment (eGFR 30-60): nirmatrelvir 150mg + ritonavir 100mg twice daily
  • Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²)
  • Contraindicated in severe hepatic impairment (Child-Pugh Class C)
  • Multiple high-risk conditions include age >50, diabetes, heart disease, lung disease, obesity, immunocompromised state
  • Pregnancy is a high-risk condition but requires careful risk-benefit assessment
  • Unvaccinated or not up-to-date vaccination status increases eligibility
  • Complete drug interaction screening essential before prescribing
  • May be used in vaccinated patients who remain at high risk
  • Not recommended for patients already hospitalized due to COVID-19
  • Counsel patients on potential side effects including taste alterations and GI symptoms

Evidence & Literature Citations

  1. U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid. Updated May 2023.
  2. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408. doi: 10.1056/NEJMoa2118542.
  3. Centers for Disease Control and Prevention. Clinical Care Guidance: Oral Antiviral Treatment for COVID-19. Updated 2023.
  4. NIH COVID-19 Treatment Guidelines Panel. Ritonavir-Boosted Nirmatrelvir (Paxlovid). Updated 2023.

Score Interpretation Ranges

Not Indicated0 – 0 pts

Paxlovid not recommended

Contraindicated1 – 1 pts

Paxlovid contraindicated

Standard Dose2 – 2 pts

Paxlovid indicated - standard dose

Reduced Dose3 – 3 pts

Paxlovid indicated - reduced dose

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.